Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10908945 | Leukemia Research | 2013 | 6 Pages |
Abstract
The study found widespread use (62%) of ESA in Medicare beneficiaries with MDS. Similar ESA use rates regardless of risk status, low frequency (45%) of serum erythropoietin determination prior to ESA initiation, and high prevalence (60.4%) of short-duration ESA episodes suggest clinically important discrepancies between actual practice and guideline-recommended therapy.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Amy J. Davidoff, Sheila R. Weiss, Maria R. Baer, Xuehua Ke, Franklin Hendrick, Amer Zeidan, Steven D. Gore,